Key facts
- Redcliffe Labs’s last known valuation is $491.0M (Sep 2024).
- It has raised $122.5M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Y Combinator, Astir Ventures, Rebel Fund, Sprint VC, Kube VC — 35 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for Redcliffe Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Redcliffe Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Redcliffe Labs
Operator of a diagnostics and precision medicine company intended to offer reproductive health testing, rare diseases, and cancer gene diagnosis for patients. The company uses in-house technology to offer various screening services combined with regular counseling and clinical data management, and also provides comprehensive testing of cancer and genetic disorders, enabling patients to avail of diagnosis in all relevant aspects of pregnancy, health, and fertility care.
- Sector
- Healthcare
- HQ
- Noida, India
- Founded
- 2018
- Employees
- 1,858
- Website
- redcliffelabs.com/
- Ownership
- Privately Held (backing)
Redcliffe Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Redcliffe Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Redcliffe Labs in its N-PORT filings yet. We sweep new filings monthly.